PROPHYLAXIS OF URINARY-TRACT INFECTION IN PERSONS WITH RECENT SPINAL-CORD INJURY - A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TRIMETHOPRIM-SULFAMETHOXAZOLE

被引:57
|
作者
GRIBBLE, MJ [1 ]
PUTERMAN, ML [1 ]
机构
[1] UNIV BRITISH COLUMBIA,DEPT COMMERCE,VANCOUVER V6T 1W5,BC,CANADA
来源
AMERICAN JOURNAL OF MEDICINE | 1993年 / 95卷 / 02期
关键词
D O I
10.1016/0002-9343(93)90254-M
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE: To determine the efficacy of trimethoprim-sulfamethoxazole (TMP-SMX) for prophylaxis of urinary tract infection in persons with recent spinal cord injury, during the first 4 months of intermittent catheterization. PATIENTS AND METHODS: One hundred twenty-nine adults (112 men, 17 women) with recent acute spinal cord injury participated in a randomized, double-blind, placebo-controlled trial, and were studied for up to 16 weeks. Low-dose TMP-SMX (TMP 40 mg, SMX 200 mg) or placebo was given once daily. Clinical observations, urine cultures, and cultures of rectal and urethral swabs were made weekly. Subjects who developed breakthrough bacteriuria received conventional antimicrobial therapy and prophylaxis was continued. RESULTS: Sixty-six TMP-SMX recipients (57 men, 9 women) and 60 placebo recipients (52 men, 8 women) are evaluable for efficacy. Among male subjects, bacteriuria was present during 50% or more of study weeks in 30% of (TMP-SMX recipients and in 56% of placebo recipients (p = 0.003). The interval to the onset of bacteriuria was prolonged in TMP-SMX recipients (p <0.0001). TMP-SMX recipients without bacteriuria in any given week had a lower probability of having bacteriuria the subsequent week (0.26) than did placebo recipients (0.49) (p < 0.0001). At least 1 episode of definite symptomatic bacteriuria (bacteriuria and fever and at least 1 classical manifestation of urinary infection) occurred in 4 of 57 TMP-SMX-treated men and in 18 of 52 placebo-treated men (p < 0.0003). We observed similar trends in women, but differences did not reach statistical significance, perhaps because the number of females was small. Adverse events suspected to be due to medications were frequent in this population of patients with recent severe injuries and led to discontinuation of the study in 10% of the TMP-SMX group and 8% of the placebo group. Adverse events included neutropenia (TMP-SMX: two; placebo. three), pseudomembranous colitis (TMP-SMX: one), severe skin rash (TMP-SMX: two; placebo. one), and drug fever (TMP-SMX: one). The proportion of all episodes of bacteriuria that were due to TMP-SMX-resistant organisms was unexpectedly high in the placebo group (51%), and increased progressively according to year of enrollment in the study. By Year 3, all subjects in the placebo group had at least one episode of TMP-SMX-resistant bacteriuria. Gram-negative enteric bacilli resistant to TMP-SMX were recovered from rectal swabs (TMP-SMX 49%, placebo 42%) and urethral swabs (TMP-SMX 33%, placebo 26%) in similar proportions of subjects in the two study groups. CONCLUSIONS: Prophylaxis with TMP-SMX significantly reduces bacteriuria and symptomatic urinary tract infection in persons with recent acute spinal cord injury during bladder retraining using intermittent catheterization. However, adverse reactions attributable to TMP-SMX are common in this population. Colonization and breakthrough bacteriuria with TMP-SMX-resistant organisms are frequent and may seriously limit the usefulness of this strategy, particularly in an institutional setting.
引用
收藏
页码:141 / 152
页数:12
相关论文
共 50 条
  • [41] TRIMETHOPRIM-SULFAMETHOXAZOLE PROPHYLAXIS IN GRANULOCYTOPENIC PATIENTS WITH ACUTE-LEUKEMIA - EVALUATION OF SERUM ANTIBIOTIC LEVELS IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DEPARTMENT-OF-VETERANS-AFFAIRS COOPERATIVE STUDY
    WARD, TT
    THOMAS, RG
    FYE, CL
    ARBEIT, R
    COLTMAN, CA
    CRAIG, W
    DANA, BW
    FINEGOLD, SM
    LENTINO, J
    PENN, RL
    WEINBERG, JB
    CHOW, B
    OCHI, S
    WEBER, JH
    LAYARD, MW
    CHANG, P
    GREENBERG, P
    RIMLAND, D
    BALDIWIN, V
    MIREAULT, K
    LAWRENCE, W
    STANKO, S
    HOBBS, E
    OLMSTEAD, C
    INGRAMDRAKE, L
    NEILL, HB
    DISNEY, C
    YU, V
    HAMILTON, R
    LYMAN, GH
    LYMAN, C
    GALGIANI, J
    KIZZIER, F
    AMON, M
    GRINICH, K
    SEWELL, D
    BASSETT, R
    JACOBSON, I
    JAMES, KE
    FETTER, R
    MONTANO, L
    HICKS, R
    SATHER, MR
    YOUNG, LM
    WEBER, JH
    CLINICAL INFECTIOUS DISEASES, 1993, 17 (03) : 323 - 332
  • [42] Alendronate prevents bone loss in patients with acute spinal cord injury: A randomized, double-blind, placebo-controlled study
    Gilchrist, N. L.
    Frampton, C. M.
    Acland, R. H.
    Nicholls, M. G.
    March, R. L.
    Maguire, P.
    Heard, A.
    Reilly, P.
    Marshall, K.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (04): : 1385 - 1390
  • [43] ANTIBIOTIC-PROPHYLAXIS IN CRANIOTOMY - A PROSPECTIVE DOUBLE-BLIND PLACEBO-CONTROLLED STUDY
    VANEK, B
    DIJKMANS, BAC
    VANDULKEN, H
    VANFURTH, R
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1988, 20 (06) : 633 - 639
  • [44] THE EFFECTS OF 4 WEEKS TREATMENT WITH CISAPRIDE ON CYSTOMETRIC PARAMETERS IN SPINAL-CORD INJURY PATIENTS - A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    WYNDAELE, JJ
    VANKERREBROECK, P
    PARAPLEGIA, 1995, 33 (11): : 625 - 627
  • [45] RANDOMIZED, CONTROLLED TRIAL OF A 10-DAY COURSE OF AMIFLOXACIN VERSUS TRIMETHOPRIM-SULFAMETHOXAZOLE IN THE TREATMENT OF ACUTE, UNCOMPLICATED URINARY-TRACT INFECTION
    BOYKO, EJ
    IRAVANI, A
    SILVERMAN, MH
    SCHELLING, DJ
    WRIGHT, RA
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (04) : 665 - 667
  • [46] Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double-blind, randomized, placebo-controlled trial
    Ables, AZ
    Blumer, NA
    Valainis, GT
    Godenick, MT
    Kajdasz, DK
    Palesch, YY
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 2000, 9 (04) : 169 - 175
  • [47] A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder
    Vieta, E
    Goikolea, JM
    Martínez-Arán, A
    Comes, M
    Verger, K
    Masramon, X
    Sanchez-Moreno, J
    Colom, F
    JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (03) : 473 - 477
  • [48] ORAL IMMUNOTHERAPY IN PARAPLEGIC PATIENTS WITH CHRONIC URINARY-TRACT INFECTIONS - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    HACHEN, HJ
    JOURNAL OF UROLOGY, 1990, 143 (04): : 759 - 763
  • [49] Analgesic Efficacy of High-Frequency Spinal Cord Stimulation: A Randomized Double-Blind Placebo-Controlled Study
    Perruchoud, Christophe
    Eldabe, Sam
    Batterham, Alan M.
    Madzinga, Grace
    Brookes, Morag
    Durrer, Anne
    Rosato, Marilu
    Bovet, Nora
    West, Samantha
    Bovy, Michele
    Rutschmann, Blaise
    Gulve, Ash
    Garner, Fay
    Buchser, Eric
    NEUROMODULATION, 2013, 16 (04): : 363 - 369
  • [50] Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia
    Ushida, Takahiro
    Katayama, Yoichi
    Hiasa, Yoichi
    Nishihara, Makoto
    Tajima, Fumihiro
    Katoh, Shinsuke
    Tanaka, Hirotaka
    Maeda, Takeshi
    Furusawa, Kazunari
    Richardson, Mary
    Kakehi, Yoshihiro
    Kikumori, Kunika
    Kuroha, Masanori
    NEUROLOGY, 2023, 100 (11) : E1193 - E1206